2ayr: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= ESR1, ESR, NR3A1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | |GENE= ESR1, ESR, NR3A1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens]) | ||
|DOMAIN= | |||
|RELATEDENTRY= | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2ayr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2ayr OCA], [http://www.ebi.ac.uk/pdbsum/2ayr PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2ayr RCSB]</span> | |||
}} | }} | ||
| Line 14: | Line 17: | ||
==Overview== | ==Overview== | ||
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation. | The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation. | ||
==About this Structure== | ==About this Structure== | ||
| Line 42: | Line 42: | ||
[[Category: Wallace, O B.]] | [[Category: Wallace, O B.]] | ||
[[Category: Wang, Y.]] | [[Category: Wang, Y.]] | ||
[[Category: ligand-binding]] | [[Category: ligand-binding]] | ||
[[Category: receptor]] | [[Category: receptor]] | ||
| Line 49: | Line 48: | ||
[[Category: transcription regulation]] | [[Category: transcription regulation]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 01:59:07 2008'' | ||
Revision as of 22:59, 30 March 2008
| |||||||||||||
| 2ayr, resolution 1.900Å | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligands: | L4G | ||||||||||||
| Gene: | ESR1, ESR, NR3A1 (Homo sapiens) | ||||||||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||||||
A SERM Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats
Overview
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation.
About this Structure
2AYR is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats., Hummel CW, Geiser AG, Bryant HU, Cohen IR, Dally RD, Fong KC, Frank SA, Hinklin R, Jones SA, Lewis G, McCann DJ, Rudmann DG, Shepherd TA, Tian H, Wallace OB, Wang M, Wang Y, Dodge JA, J Med Chem. 2005 Nov 3;48(22):6772-5. PMID:16250633
Page seeded by OCA on Mon Mar 31 01:59:07 2008
Proteopedia Page Contributors and Editors (what is this?)
- Pages with broken file links
- Homo sapiens
- Single protein
- Bryant, H U.
- Cohen, I R.
- Dally, R D.
- Dodge, J A.
- Fong, K C.
- Frank, S A.
- Geiser, A G.
- Hinklin, R.
- Hummel, C W.
- Jones, S A.
- Lewis, G.
- McCann, D J.
- Rudman, D G.
- Shepherd, T A.
- Tian, H.
- Wallace, O B.
- Wang, Y.
- Ligand-binding
- Receptor
- Serm
- Transcription
- Transcription regulation
